We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Lemzoparlimab

News List

I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021 prnasia
November 05, 2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that an abstract...
I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China prnasia
December 07, 2020
I-Mab announced the advancement of clinical development of the highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (also known as TJC4) in the US and China, achieving milestones as planned.
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting prnasia
November 10, 2020
I-Mab announced initial results from its U.S. phase 1 clinical trial (NCT03934814) evaluating lemzoparlimab (also known as TJC4) for the treatment of relapsed or refractory solid tumors and lymphoma.
AbbVie, I-Mab Enter Global Immuno-Oncology Alliance contractpharma
September 07, 2020
AbbVie to pay as much as $1.74 billion for Lemzoparlimab, one of I-Mab's leading drug candidates for the treatment of multiple cancers.